CYP11B2 and chronic kidney disease: While both sodium-glucose co-transporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) or aldosterone synthase inhibitors (ASIs) have shown individual benefits in CKD, data on their combined use remain limited.